- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:06 | Day One Biopharmaceuticals GAAP EPS of -$0.72 misses by $0.06 | 3 | Seeking Alpha | ||
| Mo | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Mo | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate Progress | 104 | GlobeNewswire (Europe) | OJEMDA (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE... ► Artikel lesen | |
| Mo | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.04. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.04. | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | 27 | GlobeNewswire (Europe) | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| 23.04. | Day One Biopharma gains on FDA's accelerated nod for brain tumor treatment | 3 | Reuters | ||
| 07.03. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | Day One Biopharmaceuticals reports Q4 results | 1 | Seeking Alpha | ||
| 26.02. | Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress | 170 | GlobeNewswire (Europe) | PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023... ► Artikel lesen | |
| 17.01. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.01. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.01. | Day One Biopharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.12.23 | Day One Biopharmaceuticals, Inc.: Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 08.12.23 | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.11.23 | Day One Biopharmaceuticals, Inc.: Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine | 415 | GlobeNewswire (Europe) | BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing... ► Artikel lesen | |
| 15.11.23 | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11.23 | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2023 Financial Results and Corporate Progress | 166 | GlobeNewswire (Europe) | NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals... ► Artikel lesen | |
| 30.10.23 | Day One Biopharmaceuticals, Inc.: Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) | 299 | GlobeNewswire (Europe) | BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing... ► Artikel lesen | |
| 07.08.23 | Day One Biopharmaceuticals, Inc.: Day One Reports Second Quarter 2023 Financial Results and Corporate Progress | 238 | GlobeNewswire (Europe) | Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG)... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,665 | +1,83 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,045 | +4,92 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,968 | -2,04 % | GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener | Plant Trait Services, Protein Services, and Deployment Capabilities JONESBORO, Ark. and BOSTON, May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,390 | -1,71 % | Beam Therapeutics Inc. - 10-Q, Quarterly Report | ||
| RECURSION PHARMACEUTICALS | 8,900 | -0,45 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
| ONCOLYTICS BIOTECH | 1,070 | -2,73 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| ASSERTIO | 1,065 | -12,70 % | Assertio Holdings, Inc.: Assertio Reports First Quarter 2024 Financial Results | First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,540 | +0,81 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 10,470 | +0,77 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,015 | 0,00 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 10,330 | +1,03 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,190 | -3,58 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,370 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,810 | +3,69 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 12,240 | -0,16 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen DAY ONE BIOPHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 16,960 Euro und damit +2,17 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
